7:55AM – 9AM, January 26, 2015 – Introduction and Overview – LIVE @Silicon Valley 2015 Personalized Medicine World Conference, Mountain View, CA | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

« Hamburg, Snyderman to Address Timely Issues in Personalized Medicine at 2015 Personalized Medicine World Conference in Silicon Valley

9AM-10AM, January 26, 2015 – Newborn & Prenatal Diagnosis – LIVE @Silicon Valley 2015 Personalized Medicine World Conference, Mountain View, CA »

7:55AM – 9AM, January 26, 2015 – Introduction and Overview – LIVE @Silicon Valley 2015 Personalized Medicine World Conference, Mountain View, CA

January 26, 2015 by 2012pharmaceutical

7:55AM – 9AM, January 26, 2015 – Introduction and Overview – LIVE @Silicon Valley 2015 Personalized Medicine World Conference, Mountain View, CA

Real Time Conference Coverage with Social Media

@Computer History Museum by Dr. Aviva Lev-Ari, PhD, RN

7:55AM –Ralph Snyderman, Duke University

Ralph Snyderman, M.D., Chancellor Emeritus, Duke University

Ralph Snyderman, MD is Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine in the Duke University School of Medicine. He served as Chancellor for Health Affairs and Dean of the School of Medicine at Duke University from 1989 to July 2004 and led the transition of this excellent medical center into an internationally recognized leader of academic medicine. He oversaw the development of the Duke University Health System, one of the most successful integrated academic health systems in the country, and served as its first President and Chief Executive Officer. Dr. Snyderman has played a leading role in the conception and development of Personalized Health Care, an evolving model of national health care delivery. He was amongst the first to envision and articulate the need to move the current focus of health care from the treatment of disease-events to personalized, predictive, preventive, and participatory care that is focused on the patient. Dr. Snyderman is the recipient of numerous awards recognizing his contributions to research and to developing more rationale models of health care. In 2012, he received the David E. Rogers Award from the Association of American Medical Colleges who referred to Snyderman as “the father of personalized medicine.”

LIVE

Secepbility to disease: Biomarkers for molecular basis of inheritance.based on DISRUPTIVE TECHNOLOGIES AND INNOVATIONS. NEW form of healthcare RISK SECEPTABILITY can be tracked over time, technologies and inovations — From disease to predictive and precision Medicine. THE RIGHR DRUD for the right patient at the right time

8:00AM Peter Donnelly, Oxford University PMWC 2015 UK Introduction and Overview

Peter Donnelly, Director of the Wellcome Trust Centre for Human Genetics, Oxford University

Peter Donnelly is Director of the Wellcome Trust Centre for Human Genetics and Professor of Statistical Science at the University of Oxford. He grew up in Australia and on graduating from the University of Queensland he studied for a doctorate in Oxford as a Rhodes Scholar. He held professorships at the Universities of London and Chicago before returning to Oxford in 1996. Peter’s early research work concerned the development of stochastic models in population genetics, including the coalescent, and then the development of statistical methods for genetic and genomic data. His group developed several widely-used statistical algorithms, including STRUCTURE and PHASE, and, in collaboration with colleagues in Oxford, IMPUTE. His current research focuses on understanding the genetic basis of human diseases, human demographic history, bacterial evolution and infection, and the mechanisms involved in mammalian recombination. Peter played a major role in the HapMap project, and more recently, he chaired the Wellcome Trust Case Control Consortium (WTCCC) and its successor, WTCCC2, a large international collaboration studying the genetic basis of more than 20 common human diseases and conditions in over 60,000 people. He also leads WGS500, an Oxford collaboration with Illumina to sequence 500 individuals with a range of clinical conditions, to assess the short-term potential for whole genome sequencing in clinical medicine. Peter is a Fellow of the Royal Society and of the Academy of Medical Sciences. LIVE – Chair of the WELLCOME TRUST.

In April 2015 same conference in Oxford, UK. Sequencing 100,000 patients in the British Universal Health System by 2017.

8:05AM Amir Dan Rubin, Stanford Health Care Stanford Health Care Delivery Innovation

Amir Dan Rubin, President & CEO, Stanford Health Care

Amir Dan Rubin serves as President and CEO of Stanford Hospital & Clinics in Palo Alto. He previously served as COO for the UCLA Hospital System, responsible for the operations of the Ronald Reagan UCLA Medical Center, Mattel Children’s Hospital at UCLA, the Resnick Neuropsychiatric Hospital at UCLA, Santa Monica-UCLA Medical Center and Orthopedic Hospital, among others. Prior to UCLA, Amir served as COO for Stony Brook University Hospital where he was involved in efforts to improve quality, operations, and the patient experience. Prior to Stony Brook, Amir served as a VP of Operations for Memorial Hermann Hospital in Houston, and before that he was Director of Business Development for the corporate parent of the Memorial Hermann Healthcare System.

LIVE from the Podium

How Stanford Healthcare system integrates: Science, Compassion one patient at a time. Innovations in the PM area: Monoclonal antibodies, Deep sequencing in blood circulation tumor cells, using biomarkers vs other diagnostics more invasive. Clinical Care: transforming Coordinated Care, Bashboard for the physician to know what to order.

C-i-Care – platform for patients decision support tools, Neuro HealthCare and Genomics is an example for precision medicine

Virtual Care Innovation – platforms for Personalized and MOBILE care, On-line telecom visit with MDs.

8:15AM Craig Venter, JCVI

Craig Venter, Ph.D., Founder & CEO, JCVI

J. Craig Venter is regarded as one of the most forward-looking scientists of the 21st century for his progressive innovations and contributions to genomic research. He is the founder and president of the J. Craig Venter Institute and J. Craig Venter Science Foundation as well as the founder and chairman of the Institute for Genomic Research (TIGR). Dr. Venter has played a vital role in the expeditious sequencing and analysis of the human genome using the methodology of “shotgun sequencing”. His accomplishments in the development of methods for decoding genetic sequences, notably expressed-sequence tags (ESTs), not only helped identify new genes and explore their functions, but also provided a foundation for understanding the relationships between species and the biology of microbes.

LIVE from the Podium

Human Longevity: combining Phynotype with Genotype information for purposes of Predictions. Digitization of the genotype information, many species, bacterias to eurucyrte cell based systems. Syntathising chromosones – synthesize, DNA is a SOftware of life, change in code means change in life.

Interpretation of the Humane Genome is very important in parallel to obtaining more species having a sequenced genome. Inexpensive sequencing solutions, boxes of Sequencers – HLI in LaJolla, Clinical Center and Sequencing Center, Collaboration with Google in Mountain View.

Global Sequencing PacBio Assembly and Scaling. Haploid cells for genome, Sequencing of isolated sperm cells to identify COMPOUND HETEROZYGOTS — compound mutation architecture. WGS in Cancer CAre – Success in Grug: Herceptin, XAKORI, KALYDECO.

HUMAN MICROBIOMES – Metabolomics – GE 7T Whole body MRI – new MRI Imaging algorithms to understand predictions – Brain mapping for Decoding the Brain

Human Phenotyping: collecting data in Brazil.Integrating data better. DB Size: Raw vs Features. Multi-task learning

An Integrative Approach to Medicine – Data vs Knowledge — == — Prediction

8:30 AM Ron Davis, Stanford

Ron Davis, Ph.D., Director, Stanford Genome Technology Center

Dr. Ron Davis developed the R-loop technique of electron microscopy for mapping coding RNA’s which led to the discovery of RNA splicing. Dr. Davis was the first to demonstrate the use of restriction endonucleases for joining DNA fragments. Dr. Davis was a co-collaborator in the development of the first DNA microarray for gene expression profiling, and the gene expression profile of the first complete eukaryotic genome. He is a Professor of Biochemistry & Genetics, and Director of the Stanford Genome Technology Center at Stanford University where he is a researcher in biotechnology and molecular genetics, particularly active in human and yeast genomics and the development of new technologies in genomics, with over 30 biotechnology patents.”

LIVE FROM THE PODIUM

From Stanford Medical Center – Department of Genomics – Stanford Genome Technology Center: BIOCHEMISTRY — NANO-FABRICATION: high sensitivity, low cost, Direct Electrical Detection:

DNA Detection on CMOS – developed in 2000 exported to Ion Terrron in 2010
Megnetic Nanoparticle Protein RealTime assay – developed in 2005 exported to MagArray
Coaxial Nano Magnets – Magnetic beads
Horizontal Nanoneedle Arrray – Atomic Layer Deposition of Many Compounds – VO2 Temperature Transition

synthetic Biology for Natural Products Replace Antibodies

natural products have high affinitu to proteins: Affinity-based Immuno-sensor – Quantum Biosensor: Spectroscopy in nanoscale based on trunsduction of quantum tunneling current: metal electrolyte
Wearable diagnostic device for real-time biomarker monitoring

8:45AM George Church, Harvard Medical School

George Church, Ph.D., Co-developer, Human Genome Project

George Church, Ph.D. Professor of Genetics, Harvard Medical School and Professor of Health Sciences & Technology, Harvard and MIT with Walter Gilbert. He developed the first direct genomic sequencing method in 1984 and helped initiate the Human Genome Project in 1984 while he was a Research Scientist at newly-formed Biogen Inc. He invented the broadly-applied concepts of molecular multiplexing and tags,homologous recombination methods,and DNA array synthesizers. Technology transfer of automated sequencing & software to Genome Therapeutics Corp. resulted in the first commercial genome sequence, (the human pathogen, Helicobacter pylori) in 1994. He initiated the Personal Genome Project (PGP) in 2005 and research on synthetic biology. He is director of the U.S. Department of Energy Center on Bioenergy at Harvard & MIT and director of the National Institutes of Health (NHGRI) Center of Excellence in Genomic Science at Harvard, MIT & Washington University. He has been advisor to 22 companies, most recently co-founding (with Joseph Jacobson, Jay Keasling, and Drew Endy) Codon Devices, a biotech startup dedicated to synthetic biology and (with Chris Somerville) founding LS9, which is focused on biofuels. He is a senior editor for Nature EMBO Molecular Systems Biology.

LIVE from the PODIUM

Synthetic Biology Originator – Testing Human Genome Interpretation

Moore’s Law on decrease the cost of sequencing a Genome while error rate decrease exponential as well.
NextGen CROSPR, Caribou Biosciences, addgene, egenesis, editas, Sigma/CRISPR
Hope from Pig to Organs
CRISPR –>> Human Organoids-on-ChipsL Wyss Institute: PAtients Mutations -> normal hiPSC–>> Cardiomyocytes – morphology abnormality –.. Targeted & Genome-wide
NIST +FDA Genomeinabottle.org and PersonalGenomes.org – Cohorts consented to sequencing og Genomes
Age NAD loss reversal via CRISPR TFAM activation
VPR Activation- multiplexed Activation of endo
epigenetics and CRISPR: FISSEQ 3D RNA – Fluorescent in situ sequencing – FISH Sequencin – Automated FISSEQ – Fibronecting nRNA – multiple identifiable reads
Super -resolution DNA: multiple
Expansion microscopy
In situ multiplex Proteomix
Genome Engineering Demos – 4Mbp Genomically Recorded Organism (GRO)
REGENESIS